Hims & Hers Health Stock Drops 7.72% Amidst 21st Ranked Trading Volume as Wegovy Pricing Initiative Unveiled

On May 22, 2025, Hims & Hers Health (HIMS) experienced a significant decline, with its stock price dropping by 7.72%, marking the fourth consecutive day of losses and a total decrease of 17.22% over the past four days. The trading volume for the day was 26.37 billion, ranking it 21st in the market.

Hims & Hers Health has introduced a new pricing structure for Wegovy®, a prescription-only medication for obesity treatment. New customers on the Hims & Hers platform can now access Wegovy® for $549 per month for a period of six months. This limited-time offer aims to make obesity care and treatments more accessible and affordable for millions of Americans. The company's CEO and co-founder, Andrew Dudum, emphasized the commitment to increasing access to care for customers through sustainable and long-term solutions.

This initiative is part of Hims & Hers' broader strategy to provide a comprehensive and holistic approach to weight loss. The platform offers a range of treatment options, including other medications, oral kits, protein, nutrition kits, and clinically-backed care plans. These resources are designed to help customers start and sustain their health journeys based on their individual needs and goals.